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ABSTRACT The protonation state and intracellular distribution of ellipticine were investigated in single human mammary T47D
cells by confocal laser microspectrofluorimetry. In the cell nucleus, only the protonated form of ellipticine was detected as a direct
consequence of its apparent pK increase upon DNA binding. Both protonated and neutral forms were present in the aqueous
cytoplasm, where the pH is close to the drug pK. When cells were incubated in high concentrations of K+, a condition that
depolarizes the plasma membrane potential, ellipticine cellular accumulation was reduced. In the cytoplasm, ellipticine was
mainly bound to mitochondria, and its protonation equilibrium was shifted toward the neutral form. The fluorescence spectrum
of ellipticine bound to mitochondria was insensitive to valinomycin, whereas it was markedly shifted toward the protonated form
after carbonyl cyanide p-trifluoromethoxy-phenylhydrazone or nigericin addition. Similar studies with ellipticine bound to isolated
mitochondria suggest that it behaves as a fluorescent probe of mitochondrial pH in both isolated mitochondria and single living
cells.
INTRODUCTION
The pioneering study by Lermann on the mechanism of pro-
flavine binding to DNA was the first to propose the inter-
calation model, which consists of the insertion of planar aro-
matic compounds betweenDNAbase pairs (Lermann, 1961).
Since this first description of the model, considerable re-
search has been oriented toward the generalization of this
drug-DNA binding mode to numerous other polycyclic
planar molecules and to the understanding of its biological
consequences, especially in pharmacology. Thus, some mol-
ecules in the series of anthracyclines, actinomycins, acri-
dines, and ellipticines have been successfully used to treat
human malignancies (Baguley, 1991). However, until now,
the relationships between drug-DNA binding and antitumor
activity have not been fully demonstrated. Moreover, the
genuine subcellular target(s) of the drug, which induces the
primary cytotoxicity, has not yet been fully established. De-
spite the high affinity of these molecules for DNA in vitro,
several studies have shown that inside the cell, the available
drugs were mainly located in the cytoplasm exhibiting a
speckled distribution (Charcosset et al., 1983; Larsen et al.,
1986; Auclair et al., 1988). This suggests that they are mainly
localized within some cytoplasmic organelles. In addition,
previous in vitro studies on isolated mitochondria have
shown that anthracyclines (Goodmaghtigh et al., 1982;
Porumb and Petrescu, 1986) and ellipticines (Dupont et al.,
1987, 1990) behave as powerful metabolic inhibitors of oxi-
dative phosphorylation. If a similar mitochondrial interaction
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could occur in an intact cell, it would cause severe changes
in the cell's metabolism. Knowledge of the mechanisms gov-
erning the subcellular distribution of these drugs is therefore
relevant to understanding their cytotoxic pathway. Antitu-
mor drugs in the series of anthracyclines (Burke et al., 1987),
acridines (Denny et al., 1987), or ellipticines (Dodin et al.,
1988) are all weak bases, with pKs of protonation ranging
between 7.4 and 8.5. Thus, inside the cell, these molecules
exist in their two protonation states, namely the cationic pro-
tonated form and the neutral form. The protonation equilib-
rium can be shifted as a function of the interactions of these
molecules with biological macromolecules (Dodin et al.,
1990) or their accumulation in organelles, such as lysosomes
and mitochondria, where a specific local pH exists (Rotten-
berg, 1989). In the present study, we investigated the rela-
tionships between the protonation state of antitumor alka-
loids and their accumulation in different cell compartments,
using ellipticine as the model. Ellipticine appeared to be a
good candidate for such a study, since it displays a high
fluorescence quantum yield, its pK of protonation (7.4) is
close to the cytoplasmic pH, and its unprotonated (neutral)
and protonated (cationic) forms exhibit specific fluorescence
emission spectra. The patterns of ellipticine nuclear and cy-
toplasmic staining were examined in living T47D cells by
means of confocal laser microspectrofluorometry. This tech-
nique was chosen for its high spatial and spectral resolution,
which makes possible the simultaneous determination of
drug's localization and protonation state. Fluorescence emis-
sion intensities and spectra recorded from different cell com-
partments were compared to those obtained in vitro when
ellipticine was bound to isolated chromatin and mitochon-
dria. Specific ionophores were used to investigate the re-
spective influence of transmembrane Aqp and ApH on the
drug protonation state.
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MATERIALS AND METHODS
Chemicals
Ellipticine was a generous gift from Dr. E. Lescot (Institut Gustave Roussy,
Villejuif, France). It was routinely checked for purity by both thin-layer
chromatography and high-performance liquid chromatography. An aqueous
stock solution of ellipticine (hydrochloride) was stored at -20°C and used
within 2 weeks. Working solutions of the drug were prepared immediately
before each experiment by diluting the stock solution, and then the drug
concentration was determined by UV absorption.
Calf thymus DNA (highly polymerized sodium salt), carbonyl cyanide
p-trifluoromethoxy-phenylhydrazone (FCCP), and nigericin were pur-
chased from Sigma Chemical Co. (St. Louis, MO). DNA was dissolved in
0.01 M acetate buffer (pH 5) and sonicated for -3 min at 4°C in order to
reduce its viscosity. Sodium dodecyl sulfate and Triton X-100 were of the
highest available grade and were used as such or after reprecipitation from
water (except for Triton X-100) without any significant difference. The
mitochondrial probe JC-1 was purchased from Molecular Probes (Eugene,
OR).
Dimyristoyl phosphatidyl glycerol liposomes and dimyristoyl phospha-
tidyl choline liposomes were prepared and characterized as previously de-
scribed (Aubard et al., 1990). For pK determinations, the following buffers
were obtained from Merck: pH 5 (0.025 M acetate), pH 7 (0.025 M phos-
phate), pH 8 (0.025 M borate), pH 9 (0.025 M borate), pH 11 (0.025 M
borate); mixtures of pH 9 and pH 11 were used to obtained various pHs
within this range. NaCl was added to these buffers to obtain a final salt
concentration of 0.1 M.
Cell culture
Human T47D mammary tumor cells, isolated from the pleural effusion
fluids of a patient with breast carcinoma (Keydar et al., 1979), were obtained
from Dr. H. Magdelenat (Institut Curie, Paris, France). The cells were grown
as monolayers (25 cm2 flasks) in RPMI 1640 with 10% fetal calf serum,
L-glutamine (2mM), and penicillin-streptomycin (50 IU/ml, 50,ug/ml, re-
spectively), all purchased from Boehringer Mannheim (Meylan, France).
The cells were maintained in a humidified atmosphere of 95% air/5% CO2
at 37°C. Confluent cultures were used for all experiments.
Isolation of nuclei
Mouse leukemia L1210 cells, collected 7 days after passage into three
DBA/2 mice were suspended, at 4°C, in 100 ml of a buffer containing 0.25
M sucrose and 5 mM EDTA (pH 8) and centrifuged for 5 min at 1500 X
g. The cells were then washed twice in the same buffer and then homog-
enized in buffer containing Tris-HCl 10mM (pH 8), 75 mM NaCl, 0.1 mM
phenylmethylsulfonyl fluoride, and 26 mM EDTA. The homogenate was
centrifuged at 1000X g for 5 min, and the supermatant was discarded. The
pellet was then suspended in the same buffer containing 0.25% (v/v) of
Nonidet P40. The suspension was incubated at 4°C for 40 min, under gentle
stirring, and centrifuged at 100 X g for 5 min. The nuclei were then washed
3 times in 0.35 M sucrose and 0.1 M EDTA (pH 8).
Chromatin isolation
The nuclei were resuspended in 10 mM Tris-HCl (pH 7.4), 40 mM NaCl,
3mM MgCl2, and1 mM CaCl2. Nuclei were digested at 37°C for 5 min
in the presence of 150 units/ml micrococcal nuclease (Boehringer). The
digestion was stopped by cooling to4°C and the addition of EDTA to a final
concentration of 10 mM. The digested nuclei were dialyzed for 12 h against
a buffer containing 80 mM NaCl, 5 mM Tris-HCl (pH 7.4), and 0.2 mM
EDTA. After homogenization, the suspension was centrifuged for 5 min at
800 X g, and the supernatant contained the soluble chromatin. The chro-
matin concentration was expressed as its DNA content, determined by its
UV absorbance at 260 nm, assuming that 50ag/ml of chromatin corre-
sponds to an optical density of 1.1 at this wavelength. For drug binding
experiments, the chromatin was dialyzed overnight at 4°C against 10 mM
cacodylate buffer (pH 7.0), containing 0.2 mM EDTA and 10 mM NaCl,
and further diluted in the same buffer to obtain a final concentration of -300
,uM as expressed in nucleotides.
Isolation of mitochondria
Rat liver mitochondria from male Wistar albino rats (150-200 g) were pre-
pared by differential centrifugation through a medium containing 0.225 M
mannitol, 0.075 M sucrose, 10 mM 4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid (pH 7.2), 0.2 mM EDTA, and 0.1% bovine serum al-
bumin. Rat liver (3 g) was cut into small pieces, ground in a potter ho-
mogenizer in 20 ml of medium at 40C, and centrifuged at 750 X g for 10
min. The supernatant was centrifuged at 8700 X g for 10 min. The pellet
was superficially washed twice with 10 ml of medium and centrifuged at
6000 x g for 10 min in order to remove the fluffy layer. The final pellet
was suspended in 500 ,ul of ice-cold homogenization medium. The mito-
chondrial protein content was determined using the method of Lowry et al.
(1951) and bovine serum albumin as the standard.
Fluorescence titration experiments
These experiments were performed using an LS 50 Perkin-Elmer spectro-
fluorometer, in quartz fluorescence cells (1-cm path length) containing 3 ml
of buffered solution. Before titration, excitation and emission spectra of the
drug in the absence and the presence of an excess of either chromatin or
mitochondria were recorded. Addition of DNA, chromatin, or mitochondria
to a solution of ellipticine led to a marked increase in fluorescence intensity
associated with a shift toward the red end of the excitation spectrum
(Schwaller et al., 1989). The amount of ellipticine bound to macromolecules
or mitochondria (Cb) was calculated from the increase of the fluorescence
emitted by the ellipticine chromophore upon binding, according to the fol-
lowing equation:
Cb = [AIf/k(V - 1)],
where Alf is the difference between the fluorescence intensities emitted by
free and bound ellipticine, V is the ratio of the fluorescence quantum yield
of bound to free drug at 520 nm, and k is a factor that converts free drug
concentration to fluorescence intensities.
Values of r, the ratio of bound ellipticine to chromatin or mitochondriae
concentrations, and C, the free drug concentration calculated from binding
experiments, were analyzed routinely according to Scatchard's equation
(Scatchard, 1949):
rIC=K(n - r)
where K (given by the slope of the Scatchard plot) represents the ellipticine
association constant to an isolated site and n (given by the intercept of the
r-axis) represents the maximum number of ellipticine molecules bound per
nucleotide (in DNA or chromatin binding experiments) or per phospholipid
(in the case of mitochondria), assuming that rat liver mitochondria contain
200 nmol phospholipids/mg protein (Rottenberg, 1984).
Microspectrofluorometry
The UV-visible confocal laser microspectrofluorometer prototype was built
around a Zeiss UMSP 80 UV epifluorescence microscope (Carl Zeiss, Inc.,
Oberkochen, Germany), optically coupled by UV reflecting mirrors to a
Jobin-Yvon HR640 spectrograph (ISA, Longjumeau, France) (Sureau et al.,
1990). The 351-nm UV line of an argon laser (model 2025; Spectra-Physics,
Mountain View, CA) was used for drug excitation. The diameter of the laser
beam is first enhanced through a double-lens beam expander in order to
cover the entire numerical aperture of the microscope's optics. The laser
beam is then deflected by the epi-illumination system (dichroic mirror or
semireflecting glass) and focused on the sample through the microscope
objective (X63 Zeiss Neofluar water-immersion objective; numerical ap-
erture= 1.2) on a circular spot 0.5gmm in diameter. The excitation power
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is reduced to less than 0.1 ,uW by neutral optical density filters. The ob-
jective was immersed in the culture medium, and a circular area 0.8 ,um in
diameter was selected at the sample level, by interposing a field diaphragm
on the emission pathway of the microscope, to selectively collect the fluo-
rescence signal from the nucleus or a specific cytoplasmic area. Confocal
conditions are met when the image of this analysis field diaphragm through
the microscope objective perfectly coincides with the focus of the laserbeam
on the sample. Under these conditions, the experimental spatial resolution,
measured on calibrated latex beads (2, 0.6, and 0.16 ;um in diameter) labeled
with the fluorescent probe fluorescein, is 0.5 ,um for the directionsX, Y, and
Z. Finally the fluorescence spectra were recorded after spectrograph dis-
persion, in the 380-630 region on a 1024 diode-intensified optical multi-
channel analyzer (Princeton Instruments, Inc., Princeton, NJ) with a reso-
lution of 0.25 nm/diode. Each fluorescence emission spectrum was collected
for 1 to 10 s. Data were stored and processed on an 80286 IBM PS/2
microcomputer using the Jobin-Yvon "Enhanced Prism" software. It should
be noted that, in order to avoid any possible fluorescence from a plastic or
glass support during analysis with near-UV excitation, cells were grown on
quartz plates that were then placed on the microscope stage in 50-mm ther-
mostated Petri dishes, filled with 5 ml ofphosphate-buffered saline. A uranyl
glass bar was used as a fluorescence standard to control laser power and
instrumental response and to enable quantitative comparison between spec-
tra recorded on different days. Sample heating, photobleaching, and pho-
todamage were assessed empirically and found to be negligible under our
experimental conditions. In particular, cells always remained viable after
repeated fluorescence determinations, as controlled by phase-contrast
microscopy.
Fluorescence image of JC-1 -stained T47D cells
JC-1 is a carbocyanine cationic dye that can be exploited for imaging live
mitochondria on the stage of a microscope. It has an advantage over rho-
damines and other carbocyanines in that its color changes reversibly from
green to red in response to the membrane potential of energized mitochon-
dria (Reers et al., 1991; Smiley et al., 1991). Photomicrographs of stained
mitochondria in cells were obtained with the microspectrofluorimeter sys-
tem hooked up to an Olympus OM2 camera, using a 50-W mercury arc lamp
for JC-1 excitation and the appropriate filters: Zeiss barrier (LP 520 nm),
dichroic mirror (FIT 510 nm), and exciter (450-490 nm), as previously de-
scribed (Smiley et al., 1991). Fluorescent images were recorded on 400 ASA
Ektachrome positive film and printed on Konica paper.
RESULTS
Protonation state of ellipticine free or bound to
DNA, chromatin, model membranes, or
mitochondria
Ellipticine can be protonated at its N(2) nitrogen atom (see
chemical formula). The unprotonated (neutral) form of el-
lipticine presents a characteristic UV absorption band at 290
N
H CH3
Chemical formula of ellipticine
nm and a typical emission band at 430 nm, whereas the cat-
ionic (protonated) form of the drug shows an absorption band
peaking at 310 nm and an emission band at 520 nm (Fig. 1).
The pK of protonation of the drug can be determined from
either absorption (ratio of absorbances at 290/310 nm versus
pH) or fluorescence spectroscopy (ratio of emissions at 430/
520 nm versus pH). As shown in Table 1, the intrinsic pro-
tonation pK (pKi) of ellipticine in water is 7.4. When ellip-
ticine was bound to neutral hydrophobic structures, such as
Triton X-100 micelles or zwitterionic liposomes (dimyristoyl
phosphatidyl choline liposomes), its pKppwas -6 as a result
of the reduced polarity at the interface, as previously de-
scribed for other lipoid pH indicators (Mukerjee and Baner-
jee, 1964; Fernandez and Fromhertz, 1977). By contrast,
when ellipticine was bound to anionic macromolecules such
as dimyristoyl phosphatidyl glycerol liposomes or DNA, its
apparent pK (pKapp) was increased to -9. These pKapp in-
creases can be interpreted as resulting from an enhanced
proton activity at the anionic interface (Fernandez and From-
hertz, 1977) according to Boltzmann's law:
ai = aw exp (-FAp/RI)
where aw is the proton activity in the bulk water, At is the
interfacial potential, R is the general gas constant, F is Fara-
day's constant, and T is the temperature in 'K. The apparent
pK is then given by the following expression (Fernandez and
Fromhertz, 1977):
pKapp - pKI( = -FAq/2.3RT.
The apparent pK of ellipticine bound to chromatin, as com-
pared to pure DNA, was lower (pKapp = 8.5 and 9.1, re-
spectively) (Fig. 2). This effect can also be interpreted taking
into account the partial neutralization of the DNA/water in-
terface by lysine-rich histones (Larue et al., 1987). When
bound to mitochondria, the ellipticine pKapp was -7.5 (Table
1), which suggests that the ellipticine binding domain in the
membrane is composed of a mixture of both neutral (pKapp
-6) and anionic phospholipids (pKapp -9).
Binding to DNA, chromatin, and mitochondria
As previously described for ellipticine, its derivatives, and
other DNA-intercalating drugs, it is expected that free mol-
ecules in aqueous solution and those bound to DNA
(Schwaller et al., 1989), chromatin (Larue et al., 1987), or
model membranes (Aubard et al., 1990) will have different
fluorescence properties. Accordingly, the addition of DNA,
chromatin, or mitochondria to a solution of ellipticine led to
a marked increase in fluorescence intensity. The increased
fluorescence emitted as a function of ellipticine binding,
expressed as the ratio of the intensities of bound to free
fluorescence, was estimated from extrapolation of a double-
reciprocal plot of fluorescence increase versus macromol-
ecule concentration as shown in Fig. 3 for binding to mito-
chondria. The ratio of fluorescence intensities obtained for
ellipticine bound to DNA, chromatin, or mitochondria over
free ellipticine are given in Table 1. The Scatchard plot ob-
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FIGURE 1 Fluorescence emission spectra of an
aqueous solution of ellipticine at the following pH
values (25°C): (1) pH = 6.0; (2) 7.4; (3) 8.9; (4)
11.2; (5) 12.2. Excitation wavelength, 290 nm.
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TABLE 1 Apparent pK and binding parameters of ellipticine
with various macromolecules
Macromolecules pKapp* V1 K (106 M-1)§ nll
H20 7.4 1
CT-DNA 9.1 17
Chromatin 8.5 16 1.6" 0.05'
DMPG liposomes 9.2
DMPC liposomes 6.2
SDS micelles 9.4
Triton X-100 micelles 6.1
Mitochondria 7.5 11 2.0 0.05
DMPG, dimyristoyl phosphatidyl glycerol; DMPC, dimyristoyl phospha-
tidyl choline; SDS, sodium dodecyl sulfate; CT-DNA, calf thymus DNA.
*The pK of protonation was estimated from the absorbance ratio at 290 and
310 nm and from the fluorescence ratio at 430 and 520 nm (experimental
conditions are described in Materials and Methods).
WV, ratio of fluorescence intensities of bound/free ellipticine at 520 nm.
§K, association constant.
'ln, number of ellipticine molecules bound per nucleotide or phospholipid
was determined as described in Materials and Methods.
'Binding constants were estimated from the binding curve at a low
drug:phosphate ratio (high-affinity binding sites).
If
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FIGURE 2 Variation of the ellipticine 1430(520 fluorescence ratio with pH
in the bulk phase in the presence of an excess (100 ,uM as expressed in
nucleotide) of either CT-DNA (0) or chromatin (0).
tained when titrating a fixed amount of chromatin with el-
lipticine is shown in Fig. 4 a. The binding curve indicates the
presence of two types of binding sites and a positive coop-
erative binding process at a low drug:chromatin ratio, as
previously described for ellipticines and other DNA-
v-I
0.8
0.6 I
0.4I
0.2 I
0 2.106 / (M-1)
~C
FIGURE 3 Ratio of the fluorescence intensities of mitochondrial-bound
to free ellipticine measured at 520 nm in anaerobic medium containing 250
mM sucrose, 5 mM 4-morpholinepropanesulfonic acid (MOPS) (pH 7.4),
5 mM MgC92, and 5 mM succinate.
intercalating drugs (Auclair et al., 1988; Larue et al., 1987);
initial binding to the linker region induces DNA unwinding
with partial unwraping ofDNA from the core histone, which
increases the available number of binding sites. From the
slope of the titration curve obtained at a low drug:nucleotide
ratio, an association constant of 1.6 X 106 M-1 can be cal-
culated. For ellipticine binding to mitochondria, the titration
curve was linear (Fig. 4 b), indicating a single class of bind-
ing sites without any cooperative processes. From this ti-
tration curve were calculated an association constant of
-2 X 106 M1 and a maximum number of bound ellipticine
molecules per phopholipid of -0.05. These binding param-
eters (Table 1) are close to those previously inferred from the
binding of ellipticine derivatives to model membranes
(Aubard et al., 1990).
Cytofluorescence localization of ellipticine in
T47D cells
To study the intracellular distribution of ellipticine, T47D
cells were incubated in the presence of 0.5 ,uM ellipticine for
1 h. An incubation with 1 ,uM ellipticine for 48 h reduced
the viability of this cell line to 50%. Ellipticine fluorescence
IN
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rw .aaiwj, , A.
0.1 0.15 r FIGURE 5 Epifluorescence micrograph of the localization of JC-1 in
T47D cells. The yellow emission corresponds to J-aggregate fluorescence
and the green emission corresponds to JC-1 monomer fluorescence. Ex-
perimental conditions are described in Materials and Methods.
was then focused in the cytoplasm either in the cytosol or in
mitochondria, and the corresponding fluorescence spectra
were recorded (see below).
Fluorescence emission of ellipticine from three
different cell compartments
2.5
0 0.025 0.05 r
FIGURE 4 Scatchard isotherms for the binding of ellipticine to chromatin
(a) or energized mitochondria (b). (a) 10mM cacodylate buffer, 0.1 M NaCl
(pH 7.4). (b) aerobic medium containing 250 mM sucrose, 5 mM MOPS
(pH 7.4), 5 mM MgCl2, and 5 mM succinate.
The ellipticine protonation state was analyzed in three dif-
ferent cell compartments of T47D cells using confocal laser
microspectrofluorometry; the emission spectrum from a se-
lected microvolume within the cell nucleus presented a single
band centered at 520 nm (Fig. 6, spectrum 2). This single
band, which characterizes the emission of the protonated cat-
ionic form of the drug (cf. Fig. 1), was identical to the emis-
sion band recorded from DNA-bound ellipticine (Fig. 6,
spectrum 3), suggesting that, in the cell nucleus, the drug
binds to DNA, in its cationic state, as would be expected from
was principally located in the cytoplasm, and a weaker fluo-
rescence emanated from the nucleus. Moreover, using dif-
ferent cell lines, it was previously shown that, in the cyto-
plasm, ellipticine fluorescence was mainly localized in
granular structures (Charcosset et al., 1983; Larsen et al.,
1986; Auclair et al., 1988). Taking into account that ellip-
ticine interacts strongly with mitochondria in vitro (Dupont
et al., 1987, 1990), we tentatively analyzed the ability of
ellipticine to localize at the level of intracellular mitochon-
dria. To measure the specific fluorescence emission spec-
trum of ellipticine interacting with mitochondria, T47D cells
were preincubated with JC-1, a specific energy potential-
dependent mitochondrial fluorescent probe (Reers et al.,
1991; Smiley et al., 1991) that forms red fluorescent
J-aggregates when it accumulates in mitochondria. Thus, a
mitochondriae localization (Fig. 5) was first observed by
fluorescence imaging at 490 nm (see Materials and Meth-
ods). The 351-nm laser line, used for ellipticine excitation,
If
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FIGURE 6 Microspectrofluorometric spectra emitted from a selected mi-
crovolume of the T47D cell nucleus before (spectrum 1) and after incubation
with 0.5 ,M ellipticine for 5 h (spectrum 2) and comparison with the fluo-
rescence emission spectrum of ellipticine bound to CT-DNA (DNA/
ellipticine = 100) (spectrum 3). Experimental conditions are described in
Materials and Methods.
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its apparent pK for isolated DNA and chromatin (Table 1).
When the laser beam was focused in cytosol, the emission
spectrum (corrected for cell intrinsic fluorescence) consisted
oftwo bands centered at -430 and 520 nm, respectively (Fig.
7, spectrum 1), with an intensity ratio (1520/1430) of -3. These
two bands are characteristic of the neutral (blue band) and
protonated (green band) forms, which suggested that the drug
existed in its two protonation states in the cytosol, as would
be expected from the pH of this cell compartment. Cells were
also incubated in medium containing high concentrations of
K+, to specifically collapse the plasma membrane potential
(Andrews et al., 1991). Under these conditions, the cytosolic
fluorescence intensity decreased, essentially because of a de-
crease in the protonated form to approximately one-third of
its initial value (Fig. 7, spectrum 2). This observation con-
firms that the distribution of the protonated form between
cytosol and external medium is governed by the plasma
membrane potential, as previously described with ellip-
ticinium derivatives (Charcosset et al., 1984; Sautereau and
Trombe, 1986). When the laser beam was focused on mi-
tochondria, a fourfold increase of the whole fluorescence
intensity (relative to cytosol) was observed (Fig. 8, spectrum
1). Moreover, the ratio (152011430) of the two specific fluo-
rescence bands was markedly decreased to --1. The relative
enhancement of the blue emission band revealed that, in this
area, the ellipticine protonation equilibrium was shifted to-
ward the neutral form. Since the pH of the whole cytosol was
buffered near neutrality, the only subcellular compartment
displaying alkaline conditions and in which ellipticine might
have accumulated was the inner mitochondrial membrane-
matrix interface (Dupont et al., 1990; Rottenberg, 1989). To
confirm this hypothesis, intracellular fluorescence spectra
were recorded in the presence of specific mitochondrial iono-
phores. When T47D cells were incubated with 5 ,uM FCCP,
a protonophore that specifically collapses the mitochondrial
proton electrochemical gradient (A,uH+) (Johnson et al.,
1981), the I520/1430 ratio was markedly increased (Fig. 8,
If 2
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FIGURE 8 Effect of FCCP, valinomycin, and nigericin on the ellipticine
fluorescence spectrum emitted from mitochondria in T47D cell cytoplasm.
Spectra were corrected for the intrinsic fluorescence before drug incubation
(0.5 AM ellipticine for 5 h). The laser was focused on mitochondria before
(spectrum 1) and after the addition of FCCP (spectrum 2), valinomycin
(spectrum 3), or nigericin (spectrum 4).
spectrum 2). This observation suggests that the blue emission
band of ellipticine was mainly associated with energized
mitochondria. To determine whether the change in ellipticine
fluorescence bound to energized mitochondria was due to the
A or to the ApH component of the proton electrochemical
gradient, cells were incubated with the ionophore valino-
mycin to specifically investigate the influence of the mito-
chondrial membrane potential. Valinomycin is a K+ iono-
phore that slightly hyperpolarizes the plasma membrane but
depolarizes the mitochondrial membrane potential (Johnson
et al., 1981). When 2 ,uM valinomycin was added to T47D
cells loaded with ellipticine, the I520/1430 ratio was unaffected
(Fig. 8, spectrum 3). The ionophore nigericin induces an
electrically neutral exchange of protons for potassium ions
and results in the dissipation of the pH gradient across the
mitochondrial membrane (Davies et al., 1985). When nigeri-
cin (5 ,ug/ml) was added, the I520/1430 ratio was increased to
-0.8 (Fig. 8, spectrum 4). Thus, the ApH appears to be
responsible for the specific protonation state of ellipticine
bound to mitochondria. The fluorescence spectra obtained
from mitochondria within the cell were compared to those
obtained when ellipticine was bound to isolated rat liver mi-
tochondria resuspended in an aerobic buffer with succinate
as the respiratory substrate (Fig. 9). Addition of nigericin to
the suspension induced a shift of the protonation equilibrium
toward the cationic form (Fig. 9, spectrum 3). This last ob-
servation confirmed that ellipticine behaves as a fluorescent
probe of mitochondrial pH both in vitro in isolated organelles
and in single living cells.
420 540 X(nm)
FIGURE 7 Effect of the potassium concentration on ellipticine fluores-
cence emitted from a selected microvolume of T47D aqueous cytoplasm.
Spectra were corrected for intrinsic fluorescence emitted from aqueous cy-
toplasm before drug incubation (0.5 ,uM ellipticine for 5 h). Spectrum 1, 5
mM KCI; spectrum 2, 50 mM KCI.
DISCUSSION
The importance of the plasma membrane potential in the
cellular uptake and retention of charged ellipticines has pre-
viously been reported in both prokaryotic and eukaryotic cell
Biophysical Journal1 772
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FIGURE 9 Effect of the dissipation of the transmembrane ApH by ni-
gericin on the fluorescence emission of ellipticine bound to isolated mito-
chondria energized by succinate. Mitochondria (0.25 mg/ml) were sus-
pended in aerobic medium containing 250 mM sucrose, 5 mM MOPS (pH
7.4), 5 mM MgCl2, and 5 mM succinate and incubated with 0.5 ,uM el-
lipticine for S min. The fluorescence emission spectrum (Xexc = 300 nm)
was recorded before (spectrum 1) and after the addition of valinomycin
(spectrum 2) or nigericin (spectrum 3).
lines (Sautereau and Trombe, 1986; Charcosset et al., 1984).
A similar relationship between a drug's cationic charge and
its increased cellular accumulation and cytotoxicity has been
demonstrated within the anthracycline (Burke et al., 1987)
and rhodamine series (Lampidis et al., 1989; Lampidis et al.,
1990). Our data obtained with ellipticine are in agreement
with these results, since dissipation of the plasma membrane
potential ofT47D cells led to a marked decrease in ellipticine
fluorescence detected in the cytosol, especially for the cat-
ionic form. These results suggest that the protonated form of
ellipticine is sufficiently lipophilic and its positive charge is
sufficiently delocalized to allow the drug to passively cross
the plasma membrane and to accumulate in response to the
negative membrane potential. Within the cell, ellipticine is
present, as expected, in its two protonation states. Mean-
while, the drug's protonation equilibrium is highly depend-
ent on its subcellular localization. In the nucleus, the drug's
protonation equilibrium was shifted toward the protonated
form, as noted when it is bound to isolated DNA (pKapp
-9.1) and chromatin (pKapp -8.5). This observation sug-
gests that ellipticine indeed reaches the cell nucleus where it
binds, in its protonated form. Moreover, it indicates that the
apparent interfacial proton activity is higher in nuclear DNA
and chromatin than in cytosol. It would be interesting to
consider this parameter in drug-DNA complex models in
designing DNA-interacting anticancer drugs. Whereas it is
generally thought that the main pharmacological target of
ellipticine is nuclear DNA (Le Pecq et al., 1974; Auclair,
1987), our new data show that a large fraction of the drug
remains in the cytoplasm, where it exists in its two proto-
nation states. In the cytosol, neutral and cationic forms are
detected in approximately equal proportions, as would be
expected from the drug's intrinsic pK in water. This finding
suggests that, in this compartment, the drug remains essen-
tially free in solution and does not interact with neutral or
charged macromolecules, which would lead to a shift in its
pKapp, as observed in vitro (Table 1). In mitochondria, the
drug colocalized with JC-1 and its protonation equilibrium
was shifted toward the neutral form. Comparison of the ef-
fects of mitochondrial ionophores on the isolated organelles
and those in situ in the cytoplasm of T47D cells suggests that
ellipticine behaves as a fluorescent probe of the mitochon-
drial ApH both in vitro and in single living cells. From
equilibrium-binding studies with isolated mitochondria (Fig.
4 b, Table 1), it appears that the binding of ellipticine to
mitochondria is essentially a membrane interaction with
binding parameters similar to those observed with artificial
membrane models (Aubard et al., 1990) (association constant
in the range of 106 M1 and a maximal binding ratio of ap-
proximately one molecule to 20 phospholipids). If ellipticine
had accumulated in the aqueous mitochondrial matrix space,
it could probably bind to mitochondrial DNA, and as a con-
sequence, its protonation equilibrium would be shifted to-
ward the protonated form, a hypothesis that is inconsistent
with our data. Moreover, it has previously been shown that,
whereas ellipticine behaved as a potent inducer of nuclear
auxotrophic mutations in yeast, it was ineffective in the mi-
tochondrial "petite" mutation assay, even at concentrations
as high as 80 ,uM (Pinto et al., 1982). These data suggest that,
instead of accumulating in the mitochondrial matrix, ellip-
ticine remains mainly localized in the inner membrane, fac-
ing the matrix. At this site, bound ellipticine behaves as a
local pH probe, sensitive to changes in the interfacial proton
activity resulting from mitochondrial respiration. This in-
terpretation is consistent with recent bioenergetic data which
suggested that the electrogenic H+ ion movement involved
in the rise of A+, which occurs during the energy coupling
in mitochondria, does not equilibrate with the bulk aqueous
phases on either side of the mitochondrial membrane but is
essentially localized within the domain of the inner mem-
brane (McKenzie et al., 1991). In light of these observations,
it is likely that the biological effects of ellipticine binding to
mitochondria are attributable to biophysical and biochemical
interactions with the inner membrane rather than an inter-
action with mitochondrial DNA. Indeed, previous studies on
isolated mitochondria have shown that the interaction of el-
lipticine and derivatives with the inner membrane uncouples
oxidative phosphorylation and inhibits the electron pathway
at the level of cytochrome c oxidase (Dupont et al., 1987,
1990). Our data confirm that, in intact living cells, ellipticine
interacts with mitochondria. This raises the possibility that,
in addition to nuclear DNA, mitochondria could be one of the
potential targets involved in the drug's cytotoxicity mecha-
nism. When comparing fluorescence intensities detected in
nuclei and mitochondria (Figs. 6 and 8), corrected for their
respective fluorescence increases inferred from in vitro stud-
ies (Table 1), one can calculate that, at equilibrium, the drug
fraction bound to mitochondria is slightly higher than that
bound to chromatin. Accordingly, Scatchard analysis shows
that the affinity of ellipticine for mitochondrial phospholip-
ids is slightly higher than that for DNA base pairs in chro-
matin (Fig. 4 and Table 1). Since the mitochondrial volume
Sureau et al. 1 773
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is very small compared to the cytosolic volume, it is difficult
to definitively determine the local drug concentration, and
the intracellular measurements can only be interpreted quali-
tatively. Finally, it can be emphasized that, during its trans-
port from the external medium to the nucleus, the drug may
interact with its mitochondrial target before reaching nuclear
DNA. In light of these observations, it is more likely that
ellipticine cytotoxicity is primarily due to its antimitochon-
drial activity.
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